JP5537740B2 - Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法 - Google Patents

Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法 Download PDF

Info

Publication number
JP5537740B2
JP5537740B2 JP2013532213A JP2013532213A JP5537740B2 JP 5537740 B2 JP5537740 B2 JP 5537740B2 JP 2013532213 A JP2013532213 A JP 2013532213A JP 2013532213 A JP2013532213 A JP 2013532213A JP 5537740 B2 JP5537740 B2 JP 5537740B2
Authority
JP
Japan
Prior art keywords
seq
patient
binding molecule
antibody
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013532213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543501A (ja
JP2013543501A5 (enExample
Inventor
ゲトナー，アヒム
マチャケク，マッテヤ
パパヴァシリス，ハーリス
サンダー，オリバー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5537740(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013543501A publication Critical patent/JP2013543501A/ja
Publication of JP2013543501A5 publication Critical patent/JP2013543501A5/ja
Application granted granted Critical
Publication of JP5537740B2 publication Critical patent/JP5537740B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013532213A 2010-10-08 2011-10-07 Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法 Active JP5537740B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
US61/391,388 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013253745A Division JP2014114288A (ja) 2010-10-08 2013-12-09 Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法

Publications (3)

Publication Number Publication Date
JP2013543501A JP2013543501A (ja) 2013-12-05
JP2013543501A5 JP2013543501A5 (enExample) 2014-03-27
JP5537740B2 true JP5537740B2 (ja) 2014-07-02

Family

ID=44759699

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013532213A Active JP5537740B2 (ja) 2010-10-08 2011-10-07 Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
JP2013253745A Withdrawn JP2014114288A (ja) 2010-10-08 2013-12-09 Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013253745A Withdrawn JP2014114288A (ja) 2010-10-08 2013-12-09 Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法

Country Status (28)

Country Link
US (9) US9717791B2 (enExample)
EP (4) EP2625199B1 (enExample)
JP (2) JP5537740B2 (enExample)
KR (3) KR20150018595A (enExample)
CN (2) CN103154031A (enExample)
AU (1) AU2011311482B2 (enExample)
BR (1) BR112013008501A2 (enExample)
CA (1) CA2813900C (enExample)
CL (1) CL2013000930A1 (enExample)
CY (1) CY1119942T1 (enExample)
DK (1) DK2625199T3 (enExample)
ES (1) ES2660770T3 (enExample)
HK (1) HK1247932A1 (enExample)
HR (1) HRP20180301T1 (enExample)
HU (1) HUE038334T2 (enExample)
IL (1) IL225310A (enExample)
LT (1) LT2625199T (enExample)
MA (1) MA34646B1 (enExample)
MX (1) MX356279B (enExample)
NO (1) NO2625199T3 (enExample)
PH (1) PH12013500660B1 (enExample)
PL (1) PL2625199T3 (enExample)
PT (1) PT2625199T (enExample)
RU (2) RU2665954C1 (enExample)
SG (1) SG188979A1 (enExample)
SI (1) SI2625199T1 (enExample)
TW (2) TWI548419B (enExample)
WO (1) WO2012045848A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
LT3757126T (lt) 2010-11-05 2025-12-10 Novartis Ag Psoriazinio artrito gydymo būdas, panaudojant il-17 antagonistus
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JP2015504430A (ja) * 2011-11-21 2015-02-12 ノバルティス アーゲー Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
CN105307675A (zh) * 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
HK1219425A1 (zh) * 2013-03-15 2017-04-07 Amgen Inc. 使用抗il-23抗体治疗银屑病的方法
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
CN106132433B (zh) * 2013-12-27 2021-04-06 国立大学法人大阪大学 以il-17a作为靶标的疫苗
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
WO2015153144A1 (en) * 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
CN107072955B (zh) 2014-05-15 2021-06-18 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
KR102427097B1 (ko) * 2014-08-26 2022-08-01 암젠 케이-에이, 인크. 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법
CN115944734A (zh) * 2014-09-10 2023-04-11 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
CA2978431C (en) 2015-03-02 2023-10-24 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
WO2018015880A1 (en) 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2019505516A (ja) * 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
CN111032691A (zh) * 2017-08-23 2020-04-17 伊莱利利公司 生殖器银屑病的治疗
TWI808397B (zh) * 2018-09-11 2023-07-11 美商美國禮來大藥廠 治療牛皮癬之方法
CN114127108A (zh) 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
AU2020347952A1 (en) 2019-09-20 2022-04-07 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
EP4289863A4 (en) * 2020-12-17 2025-04-09 Shanghai Huaota Biopharmaceutical Co., Ltd. BISPECIFIC ANTIBODY AGAINST IL-17A AND IL-36R AND USE THEREOF
WO2022184114A1 (zh) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2116258A1 (en) * 2005-09-01 2009-11-11 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
DK1963368T6 (da) * 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
WO2008150490A2 (en) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
RU2341272C1 (ru) * 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
ES2493042T3 (es) 2008-09-29 2014-09-11 Roche Glycart Ag Anticuerpos contra la IL-17 humana y usos de los mismos

Also Published As

Publication number Publication date
JP2014114288A (ja) 2014-06-26
ES2660770T3 (es) 2018-03-26
IL225310A (en) 2016-10-31
KR20150018595A (ko) 2015-02-23
BR112013008501A2 (pt) 2016-08-16
TW201630625A (zh) 2016-09-01
WO2012045848A1 (en) 2012-04-12
US10583190B2 (en) 2020-03-10
CA2813900C (en) 2017-01-10
PT2625199T (pt) 2018-02-28
MA34646B1 (fr) 2013-11-02
SI2625199T1 (en) 2018-03-30
CN103154031A (zh) 2013-06-12
PH12013500660A1 (en) 2013-05-20
DK2625199T3 (en) 2018-02-26
JP2013543501A (ja) 2013-12-05
US20210113688A1 (en) 2021-04-22
HK1247932A1 (en) 2018-10-05
CN107029234A (zh) 2017-08-11
US20200171147A1 (en) 2020-06-04
EP3792281A1 (en) 2021-03-17
US20230321231A1 (en) 2023-10-12
TWI564022B (zh) 2017-01-01
US20250161444A1 (en) 2025-05-22
TW201216984A (en) 2012-05-01
EP4137514A1 (en) 2023-02-22
MX356279B (es) 2018-05-22
EP2625199B1 (en) 2017-11-22
NO2625199T3 (enExample) 2018-04-21
US20170304439A1 (en) 2017-10-26
CL2013000930A1 (es) 2014-03-28
AU2011311482B2 (en) 2014-05-29
HUE038334T2 (hu) 2018-10-29
US9717791B2 (en) 2017-08-01
AU2011311482A1 (en) 2013-04-04
US20210162044A1 (en) 2021-06-03
US20250161445A1 (en) 2025-05-22
CA2813900A1 (en) 2012-04-12
PH12013500660B1 (en) 2017-10-27
KR20140097566A (ko) 2014-08-06
US20250161443A1 (en) 2025-05-22
RU2013120957A (ru) 2014-11-20
EP2625199A1 (en) 2013-08-14
SG188979A1 (en) 2013-05-31
KR20130110179A (ko) 2013-10-08
CY1119942T1 (el) 2018-12-12
RU2665954C1 (ru) 2018-09-05
KR101620771B1 (ko) 2016-05-12
EP3299390A1 (en) 2018-03-28
US20130202610A1 (en) 2013-08-08
PL2625199T3 (pl) 2018-04-30
TWI548419B (zh) 2016-09-11
IL225310A0 (en) 2013-06-27
HRP20180301T1 (hr) 2018-03-23
US11534490B2 (en) 2022-12-27
RU2591083C2 (ru) 2016-07-10
LT2625199T (lt) 2018-03-12
MX2013003916A (es) 2013-06-03

Similar Documents

Publication Publication Date Title
JP5537740B2 (ja) Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
JP2024109762A (ja) Ｉｌ－１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
HK40037862A (en) Methods of treating psoriasis using il-17 antagonists
HK40088403A (en) Methods of treating psoriasis using il-17 antagonists
HK1183673A (en) Methods of treating psoriasis using il-17 antagonists
HK1183673B (en) Methods of treating psoriasis using il-17 antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131129

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20131129

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20131224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140121

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140204

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140326

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140326

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140425

R150 Certificate of patent or registration of utility model

Ref document number: 5537740

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250